Lehne's Pharmacology for Nursing Care -
Elsevier e-Book on VitalSource, 12th
Edition
by Jacqueline Rosenjack Burchum, DNSc,
FNP-BC, CNE and Laura D. Rosenthal, DNP,
RN, ACNP-BC, FAANP
TEST BANK
Lehne’s Pharmacology for Nursing Care, 12th Edition
Unit I – Introduction
Chapter 1: Orientation to Pharmacology
20 High-Yield NCLEX-Style MCQs
1. A nurse is reviewing the stages of drug development. Which
phase involves testing a new drug in a small number of healthy
volunteers to determine safety and dosage range?
A. Phase I
,B. Phase II
C. Phase III
D. Phase IV
Answer: A
Rationale: Phase I trials assess safety, pharmacokinetics, and
dosage in healthy volunteers.
Citation: Lehne’s Pharmacology for Nursing Care, 12th ed., Ch. 1
– Orientation to Pharmacology
2. A drug has completed Phase III clinical trials. What is the next
step before it can be marketed?
A. Phase IV surveillance
B. Submission of a New Drug Application (NDA)
C. Testing in animals
D. Over-the-counter approval
Answer: B
Rationale: After successful Phase III trials, the manufacturer
submits an NDA to the FDA for review and approval.
Citation: Lehne’s, 12th ed., Ch. 1
3. Which information is most important for the nurse to teach a
patient about drugs with a narrow therapeutic index?
A. The drug works quickly
B. The medication has minimal side effects
,C. Small dosage changes can cause toxicity
D. The drug is safe during pregnancy
Answer: C
Rationale: Drugs with a narrow therapeutic index require close
monitoring because small dose changes can lead to toxicity or
subtherapeutic effects.
Citation: Lehne’s, 12th ed., Ch. 1
4. A nurse explains that a medication’s generic name refers to
which of the following?
A. The brand selected by the manufacturer
B. The chemical structure of the drug
C. The official nonproprietary name
D. The marketing name used internationally
Answer: C
Rationale: The generic name is the official nonproprietary name
assigned to the drug.
Citation: Lehne’s, 12th ed., Ch. 1
5. Which resource provides the most reliable information about
a newly prescribed medication?
A. Internet search engine
B. Pharmaceutical representative brochure
C. Nursing drug reference text
D. Patient discussion group
, Answer: C
Rationale: Evidence-based drug references are reliable sources
for accurate medication information.
Citation: Lehne’s, 12th ed., Ch. 1
6. A patient reports taking herbal supplements. What is the
nurse’s priority action?
A. Document only if prescribed
B. Advise discontinuation immediately
C. Assess for potential drug interactions
D. Inform the patient herbal products are harmless
Answer: C
Rationale: Herbal products may interact with prescribed
medications and must be assessed for safety.
Citation: Lehne’s, 12th ed., Ch. 1
7. Which statement best describes Phase IV clinical trials?
A. Animal testing for toxicity
B. Post-marketing surveillance for adverse effects
C. Initial testing in humans
D. Determination of therapeutic dose
Answer: B
Rationale: Phase IV occurs after approval and monitors long-
term safety and rare adverse effects.
Citation: Lehne’s, 12th ed., Ch. 1
Elsevier e-Book on VitalSource, 12th
Edition
by Jacqueline Rosenjack Burchum, DNSc,
FNP-BC, CNE and Laura D. Rosenthal, DNP,
RN, ACNP-BC, FAANP
TEST BANK
Lehne’s Pharmacology for Nursing Care, 12th Edition
Unit I – Introduction
Chapter 1: Orientation to Pharmacology
20 High-Yield NCLEX-Style MCQs
1. A nurse is reviewing the stages of drug development. Which
phase involves testing a new drug in a small number of healthy
volunteers to determine safety and dosage range?
A. Phase I
,B. Phase II
C. Phase III
D. Phase IV
Answer: A
Rationale: Phase I trials assess safety, pharmacokinetics, and
dosage in healthy volunteers.
Citation: Lehne’s Pharmacology for Nursing Care, 12th ed., Ch. 1
– Orientation to Pharmacology
2. A drug has completed Phase III clinical trials. What is the next
step before it can be marketed?
A. Phase IV surveillance
B. Submission of a New Drug Application (NDA)
C. Testing in animals
D. Over-the-counter approval
Answer: B
Rationale: After successful Phase III trials, the manufacturer
submits an NDA to the FDA for review and approval.
Citation: Lehne’s, 12th ed., Ch. 1
3. Which information is most important for the nurse to teach a
patient about drugs with a narrow therapeutic index?
A. The drug works quickly
B. The medication has minimal side effects
,C. Small dosage changes can cause toxicity
D. The drug is safe during pregnancy
Answer: C
Rationale: Drugs with a narrow therapeutic index require close
monitoring because small dose changes can lead to toxicity or
subtherapeutic effects.
Citation: Lehne’s, 12th ed., Ch. 1
4. A nurse explains that a medication’s generic name refers to
which of the following?
A. The brand selected by the manufacturer
B. The chemical structure of the drug
C. The official nonproprietary name
D. The marketing name used internationally
Answer: C
Rationale: The generic name is the official nonproprietary name
assigned to the drug.
Citation: Lehne’s, 12th ed., Ch. 1
5. Which resource provides the most reliable information about
a newly prescribed medication?
A. Internet search engine
B. Pharmaceutical representative brochure
C. Nursing drug reference text
D. Patient discussion group
, Answer: C
Rationale: Evidence-based drug references are reliable sources
for accurate medication information.
Citation: Lehne’s, 12th ed., Ch. 1
6. A patient reports taking herbal supplements. What is the
nurse’s priority action?
A. Document only if prescribed
B. Advise discontinuation immediately
C. Assess for potential drug interactions
D. Inform the patient herbal products are harmless
Answer: C
Rationale: Herbal products may interact with prescribed
medications and must be assessed for safety.
Citation: Lehne’s, 12th ed., Ch. 1
7. Which statement best describes Phase IV clinical trials?
A. Animal testing for toxicity
B. Post-marketing surveillance for adverse effects
C. Initial testing in humans
D. Determination of therapeutic dose
Answer: B
Rationale: Phase IV occurs after approval and monitors long-
term safety and rare adverse effects.
Citation: Lehne’s, 12th ed., Ch. 1
